CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) have received an average rating of “Moderate Buy” from the six research firms that are covering the stock, Marketbeat reports. Three research analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $5.02.

Several brokerages recently weighed in on CTMX. HC Wainwright restated a “neutral” rating on shares of CytomX Therapeutics in a research report on Friday, March 7th. Wedbush reissued an “outperform” rating and issued a $5.00 target price on shares of CytomX Therapeutics in a report on Friday, March 7th. Finally, StockNews.com raised shares of CytomX Therapeutics from a “hold” rating to a “buy” rating in a report on Monday, March 10th.

CytomX Therapeutics Stock Up 1.9 %

Shares of CytomX Therapeutics stock opened at $0.63 on Friday. The firm’s 50-day moving average price is $0.74 and its two-hundred day moving average price is $0.96. CytomX Therapeutics has a 12-month low of $0.56 and a 12-month high of $5.85. The company has a market capitalization of $50.32 million, a price-to-earnings ratio of 3.70 and a beta of 1.05.

CytomX Therapeutics (NASDAQ:CTMX) last announced its quarterly earnings data on Thursday, March 6th. The biotechnology company reported $0.22 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.45. CytomX Therapeutics had a net margin of 10.96% and a negative return on equity of 41.47%. The business had revenue of $38.09 million for the quarter, compared to analysts’ expectations of $13.53 million. On average, sell-side analysts expect that CytomX Therapeutics will post -0.05 earnings per share for the current year.

Institutional Trading of CytomX Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Miller Financial Services LLC acquired a new stake in CytomX Therapeutics during the 4th quarter worth approximately $26,000. Traphagen Investment Advisors LLC acquired a new position in shares of CytomX Therapeutics during the fourth quarter worth $31,000. Algert Global LLC bought a new stake in shares of CytomX Therapeutics in the fourth quarter worth $35,000. Velan Capital Investment Management LP acquired a new stake in CytomX Therapeutics in the fourth quarter valued at $36,000. Finally, Aspire Growth Partners LLC bought a new position in CytomX Therapeutics during the 4th quarter worth $42,000. 67.77% of the stock is currently owned by institutional investors.

About CytomX Therapeutics

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.